| Print
ORYZON GENOMICS (ORY)
ORYZON GENOMICS, S.A.This share can be held in a Dealing accountSIPP
Company profile
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Oryzon Genomics SA Third Quarter Earnings Results for 2026 | 2026-11-06T00:00:00 |
| Oryzon Genomics SA Second Quarter Earnings Results for 2026 | 2026-07-30T00:00:00 |
| Oryzon Genomics SA Annual General Meeting for 2026 | 2026-06-26T13:00:00 |
| Oryzon Genomics SA First Quarter Earnings Results for 2026 | 2026-05-12T00:00:00 |
| Oryzon Genomics SA Fourth Quarter Earnings Results for 2025 | 2026-02-27T00:00:00 |
| Oryzon Genomics SA Annual Report for 2025 | 2026-02-27T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Oryzon Genomics SA Fourth Quarter Earnings Results for 2025 | 2026-02-27T00:00:00 |
| Oryzon Genomics SA Annual Report for 2025 | 2026-02-27T00:00:00 |
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12T00:00:00 |
| 9th Sachs Annual Neuroscience Innovation Forum | 2026-01-11T10:35:00 |
| Oryzon Genomics SA Third Quarter Earnings Results for 2025 | 2025-11-07T00:00:00 |
| Oryzon Genomics SA Second Quarter Earnings Results for 2025 | 2025-07-30T00:00:00 |
| Oryzon Genomics SA Annual General Meeting for 2025 | 2025-06-27T13:00:00 |
| Oryzon Genomics SA First Quarter Earnings Results for 2025 | 2025-05-12T00:00:00 |
| Oryzon Genomics SA Annual Report for 2024 | 2025-02-28T00:00:00 |
| Oryzon Genomics SA Fourth Quarter Earnings Results for 2024 | 2025-02-27T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.